Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Holding NTLA?
Track your performance easily
NTLA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.95 - $34.87
Previous Close$14.22
Volume2.60M
Average Volume (3M)1.80M
Market Cap
$1.44B
Enterprise Value$859.68M
Total Cash (Recent Filing)$691.07M
Total Debt (Recent Filing)$106.30M
Price to Earnings (P/E)―
Beta2.85
Next Earnings
Nov 07, 2024EPS Estimate
-$1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.48
Shares Outstanding101,579,188
10 Day Avg. Volume3,621,236
30 Day Avg. Volume1,796,818
Standard Deviation0.24
R-Squared0.14
Alpha0.00865
Financial Highlights & Ratios
Price to Book (P/B)1.49
Price to Sales (P/S)31.67
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.70
Enterprise Value/Gross Profit23.70
Enterprise Value/Ebitda-3.43
Forecast
1Y Price Target
$58.88Price Target Upside314.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Intellia Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Phase 2 study met its primary and all secondary endpoints, with the 50mg dose achieving a higher complete response rate compared to the 25mg dose.
Financial PositionIntellia had $940M in cash which is expected to fund operations into late-2026, providing a strong financial position.
Product DifferentiationThe 'one-and-done' nature of NTLA-2002 is seen as a significant distinguishing factor compared to competitors who require more frequent dosing.
Bears Say
Efficacy ConcernsThe reduction in HAE attacks by ~75-80% in the Phase 2 study of NTLA-2002 is seen as less impressive due to the potential risks of in vivo gene editing and competition in the market.
Financial OutlookThe outlook for NTLA shares is challenging due to the anticipated rise in company spending as Phase 3 studies progress, leading to the risk of near-term dilution.
Market CompetitionThe availability of competing HAE treatments with similar efficacy profiles is expected to be a substantial challenge for the NTLA-2002 program.
---
Ownership Overview
1.74% Insiders
21.79% Mutual Funds
12.80% Other Institutional Investors
33.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $13.95 and its highest was $34.87 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Currently, no data Available
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 5 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Aug 08, 2024. The company reported -$1.52 earnings per share for the quarter, missing the consensus estimate of -$1.217 by -$0.303.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -$1.39.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 101,579,185 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$1.52 in its last earnings report, missing expectations of -$1.217. Following the earnings report the stock price went up 5.021%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 260M.
---
Intellia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.88 (314.06% Upside)
$58.88 (314.06% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 613.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $38.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.23%
12-Months-Change
Fundamentals
Return on Equity
-49.02%
Trailing 12-Months
Asset Growth
-9.95%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
---
NTLA Earnings Call
Q2 2024
0:00 / 0:00
---
NTLA Revenue Breakdown
100.00% Collaboration revenue
---
NTLA Stock 12 Month Forecast
Average Price Target
$58.88
▲(314.06% Upside)
Technical Analysis
Best Analysts Covering NTLA
1 Year
1 Year Success Rate
13/37 ratings generated profit
1 Year Average Return
+90.28%
reiterated a buy rating 10 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 35.14% of your transactions generating a profit, with an average return of +90.28% per trade.
---